Comparative Pharmacology
Head-to-head clinical analysis: FELBATOL versus GABITRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FELBATOL versus GABITRIL.
FELBATOL vs GABITRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Felbamate is a GABA receptor agonist and modulates NMDA receptor activity, though its exact mechanism is not fully understood. It appears to enhance GABA-mediated inhibition and inhibit voltage-gated sodium channels, reducing neuronal excitability.
Tiagabine inhibits gamma-aminobutyric acid (GABA) reuptake into presynaptic neurons, thereby increasing synaptic GABA levels and enhancing inhibitory neurotransmission.
1200-3600 mg/day orally in 3-4 divided doses; initial titration recommended.
Initial dose: 4 mg orally twice daily. Titrate by 4-8 mg/day every 2 weeks. Maximum dose: 56 mg/day in 2-4 divided doses.
None Documented
None Documented
20-23 hours; steady state reached within 3-5 days; may be prolonged in hepatic impairment.
Terminal elimination half-life is 7–9 hours in healthy adults. In patients with hepatic impairment, half-life is prolonged (up to 12–24 hours) due to reduced clearance. No significant effect of renal impairment.
Renal: 40-50% unchanged; Hepatic metabolism accounts for ~50% with glucuronidation and oxidation; minimal biliary/fecal excretion (<5%).
Approximately 70% of an oral dose is excreted in feces, 25% in urine, and 5% in bile. Renal elimination of unchanged drug is minimal (<2%); most is eliminated as metabolites.
Category C
Category C
Anticonvulsant
Anticonvulsant